Bavarian Nordic A/S (OTCMKTS:BVNRY) Announces Earnings Results

Bavarian Nordic A/S (OTCMKTS:BVNRY) issued its quarterly earnings results on Wednesday. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.40 by $0.07, Zacks reports. Bavarian Nordic A/S had a net margin of 18.33% and a return on equity of 10.65%.

Bavarian Nordic A/S Stock Performance

Bavarian Nordic A/S stock opened at $8.04 on Thursday. Bavarian Nordic A/S has a twelve month low of $6.86 and a twelve month high of $14.60. The firm has a market cap of $1.90 billion, a PE ratio of 11.65 and a beta of 1.68. The firm’s 50 day moving average price is $8.55 and its two-hundred day moving average price is $9.91.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.